Therefore, tazemetostat’s safety and effectiveness have already been demonstrated and the FDA has added this drug as a therapeutic option for patients with follicular lymphoma bearing an EZH2 mutation who have already received two or more systemic therapies or patients with relapsed/refractory (R/R) follicular lymphoma and no alternative satisfactory treatment options. The gene discussed is EZH2; the disease is follicular lymphoma.